Q-omics provides the consensus-scored CD300LB profile across patient tissues and cancer cell-line models. CD300LB expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in LAML. Among the 18 cancer types available for tumor–normal comparison, CD300LB is differentially expressed in 9, with the highest sampling consensus in KIRC. Additionally, CD300LB RNA expression shows 18,797 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LAML, KIRC, and LSCC as cancer lineages where CD300LB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CD300LB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CD300LB survival associations across molecular data types. CD300LB RNA expression shows survival associations in the most cancer types (25), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CD300LB RNA expression–survival associations across cancer types. High CD300LB expression shows unfavorable associations in LAML, UVM, ACC, GBM and LGG, but favorable associations in CESC. The LAML Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LAML as the clearest survival context for CD300LB RNA expression.
This table summarizes CD300LB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CD300LB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CD300LB shows lower tumor expression in LUSC, LUAD and BLCA and higher tumor expression in KIRC, THCA and KIRP. The KIRC box plot shows higher CD300LB RNA expression in tumor versus normal tissue (log2 FC = +1.300, t-test p < 0.001).
This table shows molecular features associated with CD300LB in patient tissues and cancer cell lines. In patient samples, CD300LB shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, CD300LB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
